2250025-93-3
2250025-93-3 结构式
基本信息
Clozapine N-oxide dihydrochloride salt
8-Chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine dihydrochloride
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-17366A | Clozapine N-oxide dihydrochloride | 2250025-93-3 | 1 mg | 340元 |
| 2025/05/22 | HY-17366A | 8-Chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine dihydrochloride Clozapine N-oxide dihydrochloride | 2250025-93-3 | 5mg | 750元 |
| 2025/05/22 | HY-17366A | 8-Chloro-11-(4-methyl-4-oxido-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine dihydrochloride Clozapine N-oxide dihydrochloride | 2250025-93-3 | 10mM * 1mLin DMSO | 830元 |
常见问题列表
Human muscarinic designer receptors (DREADDs)
Clozapine N-oxide (CNO) can bind to non-DREADD receptors at concentrations required for DREADD activation, and undergoes reverse-metabolism to its parent compound clozapine, an atypical antipsychotic that acts at a variety of pharmacological targets and produces numerous physiological and behavioral effects.
After a single intraperitoneal (i.p.) injection of Clozapine N-oxide (1 mg/kg) into mice, Clozapine N-oxide (CNO) plasma levels peak at 15 min and are very low after 2 h. Despite the short plasma half-life of CNO in mice, the biological effects that have been described after acute treatment of DREADD-expressing experimental animals are usually much longer (6-10 h).